<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-09-22" updated="2019-12-02">
  <drugbank-id primary="true">DB09114</drugbank-id>
  <name>Colfosceril palmitate</name>
  <description>Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.[A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.</description>
  <cas-number>63-89-8</cas-number>
  <unii>319X2NFW0A</unii>
  <average-mass>734.0389</average-mass>
  <monoisotopic-mass>733.562155053</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31510</ref-id>
        <pubmed-id>10155285</pubmed-id>
        <citation>Bryson HM, Whittington R: Colfosceril palmitate. A pharmacoeconomic evaluation of a synthetic surfactant preparation (Exosurf Neonatal) in infants with respiratory distress syndrome. Pharmacoeconomics. 1994 Dec;6(6):563-77.</citation>
      </article>
      <article>
        <ref-id>A31515</ref-id>
        <pubmed-id>2670398</pubmed-id>
        <citation>Reynolds MS, Wallander KA: Use of surfactant in the prevention and treatment of neonatal respiratory distress syndrome. Clin Pharm. 1989 Aug;8(8):559-76.</citation>
      </article>
      <article>
        <ref-id>A31523</ref-id>
        <pubmed-id>8131363</pubmed-id>
        <citation>DeAngelis RL, Findlay JW: Metabolism of synthetic surfactants. Clin Perinatol. 1993 Dec;20(4):697-710.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T70</ref-id>
        <isbn/>
        <citation>Jackson, J.C. (2012). Avery's diseases of the newborn  (9th ed., pp. 633-646). Elsevier.</citation>
      </textbook>
      <textbook>
        <ref-id>T71</ref-id>
        <isbn/>
        <citation>Sweet D. and Speer C. (2012). The newborn lung: neonatology questions and controversies (2nd ed., pp. 283-299). Elsevier.</citation>
      </textbook>
      <textbook>
        <ref-id>T72</ref-id>
        <isbn/>
        <citation>1. (2010). In Ashcraft's pediatric surgery (5th ed., pp. 3-18). Elsevier.</citation>
      </textbook>
      <textbook>
        <ref-id>T73</ref-id>
        <isbn/>
        <citation>52. (2011). In Pediatric Critical Care (4th ed., pp. 706-716). Mosby.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L1109</ref-id>
        <title>Pharmaintelligence</title>
        <url>https://pink.pharmaintelligence.informa.com/PS017845/BURROUGHS-WELLCOMEs-EXOSURF-IS-APPROVED</url>
      </link>
      <link>
        <ref-id>L1110</ref-id>
        <title>Access</title>
        <url>http://www.syrianclinic.com/med/en/ProfDrugs/Print/ColfoscerilPalmitatepd.html</url>
      </link>
      <link>
        <ref-id>L1111</ref-id>
        <title>Curoservice</title>
        <url>http://www.curoservice.com/parents_visitors/surfactant/surfactant_composition_action.php</url>
      </link>
      <link>
        <ref-id>L1112</ref-id>
        <title>Rob Holland</title>
        <url>http://www.robholland.com/Nursing/Drug_Guide/data/monographframes/C111.html</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Colfosceril palmitate is indicated for the treatment of respiratory distress syndrome (RDS) in premature infants. The official label is referred as a intratracheal suspension for prophylactic treatment of infants of less than 1350 grams of birth weight under risk of developing RDS, or in infants with birth weight greater than 1350 grams with pulmonary immaturity, or as rescue treatment of infants that already developed RDS.[L1109] The central feature of RDS is a surfactant deficiency due to lung immaturity. This lung condition is more frequently presented due to risk factors like prematurity, delayed lung maturation caused by maternal diabetes or male gender, or surfactant dysfuntion due to perinatal asphyxia, pulmonary infection or delivery without labor.[T70]</indication>
  <pharmacodynamics>Colfosceril palmitate has shown to significantly reduce the risk of pneumothoraces, pulmonary interstitial emphysema and mortality. Unlike naturals surfactants, colfosceril palmitate reduces the risk of bronchopulmonary dysplasia, intraventricular hemorrhage and patent ductus arteriosus.[T71] In clinical placebo-controlled trials, there was a significant reduction in the number of deaths attributed to hyaline membrane disease, the incidence of pulmonary air leaks, oxygen requirements and mean airway pressure.[T72] Some reports have indicated a lack of therapeutic effect due to the absence of surfactant protein.[T73]</pharmacodynamics>
  <mechanism-of-action>Treatment with colfosceril palmitate aims to reinflate a collapsed area of the lung, improve compliance and reduce intrapulmonary shunting.[T73] The actions of colfosceril palmitate are perfomed by replacing the defficient or innefective endogenous lung surfactant and thus, reducing the tension and stabilizing the alveoli from collapsing.[L1110] Colfosceril palmitate will form a very thin film that will cover the surface of the alveolar cells and therefore it will reduce surface tension.[L1111]</mechanism-of-action>
  <toxicity>In clinical trials, there are reports of pulmonary hemorrhage when colfosceril palmitate is administered in infants with a weight of fewer than 700 grams at birth. Another potential risk of the use of colfosceril palmitate is the formation of mucus plugging in the endotracheal tube which can be prevented by performing suction prior to dosing.[L1109]</toxicity>
  <metabolism>Colfosceril palmitate is catabolized and reutilized for further synthesis and secretion in lung tissues.[L1110]</metabolism>
  <absorption>The absorption is done directly in the alveolus into the lung tissue.[L1110] As the lung surfactant is distributed in the bronchi, bronchioles and alveoli, its highest concentration is at the alveolar air-fluid interface where it remains as a monolayer.[A31515]</absorption>
  <half-life>The half-life of colfosceril palmitate is registered to be in the range of 20-36 hours.[L1112]</half-life>
  <protein-binding>Colfosceril palmitate stays and gets metabolized in the pulmunar tissue, thus it is not able to bind to plasma proteins.</protein-binding>
  <route-of-elimination>After 5 days, most of the administered dose (56%) is distributed throughout the body with renal and fecal excretion being the minor elimination pathway representing the 4 and 2% of the eliminated dose respectively. The major route of elimination is by expelled air which accounts for 28% of the administered dose.[A31523]</route-of-elimination>
  <volume-of-distribution>Colfosceril palmitate is distributed uniformly to all lobes of the lung, distal airways and alveolar spaces.[L1112] It will not enter the systemic circulation in healthy lungs, however when the integrity of the tissue is distrupted colfosceril can reach systemic circulation.[A31515] Even 5 days after administration, there are traces of colfosceril palmitate retained in the body that represented 72% of the administered dose which by then have entered pathways of lipid metabolism to become tissue associated.[A31523]</volume-of-distribution>
  <clearance>After 5 days of drug administration, the lung and liver would contain 10% of the administered dose and the elimination via renal excretion accounts only for 8% of the administered dose. This proved a very small renal clearance and confirmed that the major elimination route is by expired air.[A31523]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phosphatidylcholines. These are glycerophosphocholines in which the two free -OH are attached to one fatty acid each through an ester linkage.</description>
    <direct-parent>Phosphatidylcholines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Glycerophospholipids</class>
    <subclass>Glycerophosphocholines</subclass>
    <alternative-parent>Amines</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Dialkyl phosphates</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Fatty acid esters</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic salts</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phosphocholines</alternative-parent>
    <alternative-parent>Tetraalkylammonium salts</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Alkyl phosphate</substituent>
    <substituent>Amine</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Diacylglycero-3-phosphocholine</substituent>
    <substituent>Dialkyl phosphate</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Fatty acid ester</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic phosphoric acid derivative</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phosphocholine</substituent>
    <substituent>Phosphoric acid ester</substituent>
    <substituent>Quaternary ammonium salt</substituent>
    <substituent>Tetraalkylammonium salt</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="inn">Palmitato de colfoscerilo</synonym>
  </synonyms>
  <products>
    <product>
      <name>Exosurf Neonatal</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01927183</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2003-01-17</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Endotracheal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exosurf Neonatal</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01927175</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2003-01-17</ended-marketing-on>
      <dosage-form>Kit; Powder, for suspension</dosage-form>
      <strength/>
      <route>Endotracheal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Surfaxin</name>
      <labeller>Discovery Health</labeller>
      <ndc-id/>
      <ndc-product-code>68628-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-01</started-marketing-on>
      <ended-marketing-on>2016-01-19</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Endotracheal</route>
      <fda-application-number>NDA021746</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Surfaxin</name>
      <ingredients>1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) + Colfosceril palmitate + Palmitic Acid + Sinapultide</ingredients>
    </mixture>
    <mixture>
      <name>Exosurf Neonatal</name>
      <ingredients>Colfosceril palmitate</ingredients>
    </mixture>
    <mixture>
      <name>Exosurf Neonatal</name>
      <ingredients>Colfosceril palmitate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Glycerophosphates</category>
      <mesh-id>D005994</mesh-id>
    </category>
    <category>
      <category>Glycerophospholipids</category>
      <mesh-id>D020404</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Lung Surfactants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Membrane Lipids</category>
      <mesh-id>D008563</mesh-id>
    </category>
    <category>
      <category>Phosphatidic Acids</category>
      <mesh-id>D010712</mesh-id>
    </category>
    <category>
      <category>Phosphatidylcholines</category>
      <mesh-id>D010713</mesh-id>
    </category>
    <category>
      <category>Phospholipids</category>
      <mesh-id>D010743</mesh-id>
    </category>
    <category>
      <category>Pulmonary Surfactants</category>
      <mesh-id>D011663</mesh-id>
    </category>
    <category>
      <category>Sugar Alcohols</category>
      <mesh-id>D013402</mesh-id>
    </category>
    <category>
      <category>Sugar Phosphates</category>
      <mesh-id>D013403</mesh-id>
    </category>
    <category>
      <category>Triose Sugar Alcohols</category>
      <mesh-id>D000073999</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit; powder, for suspension</form>
      <route>Endotracheal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Endotracheal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Endotracheal</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R07AA01">
      <level code="R07AA">Lung surfactants</level>
      <level code="R07A">OTHER RESPIRATORY SYSTEM PRODUCTS</level>
      <level code="R07">OTHER RESPIRATORY SYSTEM PRODUCTS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1kb9</pdb-entry>
    <pdb-entry>2azq</pdb-entry>
    <pdb-entry>2ygn</pdb-entry>
    <pdb-entry>2ygo</pdb-entry>
    <pdb-entry>2ygp</pdb-entry>
    <pdb-entry>2ygq</pdb-entry>
    <pdb-entry>5vkq</pdb-entry>
    <pdb-entry>6giq</pdb-entry>
    <pdb-entry>6hu9</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09114.pdf?1514490433</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.29</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-7.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.40e-05 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>8.11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2-{[(2R)-2,3-bis(hexadecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2-{[(2R)-2,3-bis(hexadecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>734.0389</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>733.562155053</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C40H80NO8P</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>KILNVBDSWZSGLL-KXQOOQHDSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>111.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>215.87</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>92</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>40</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.86</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-6.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Very poor solubility</value>
      <source>Li, et al. Asian Journal of Pharmaceutical Sciences. Vol. 10. Issue 2. (2015)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>-63ºC</value>
      <source>'MSDS'</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>60.5-61.5ºC at 760 mmHg</value>
      <source>'MSDS'</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.97</value>
      <source>'MSDS'</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>922</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>72999</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>452110</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310265031</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>398235</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>PCF</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Colfosceril_palmitate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200737</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>